



Improve access to diagnosis and treatment of Alzheimer’s

- Pamplona, C.C., Collij, L.E., Ahmed, Aarsland, D., Clement, M., Bose, N., Kuhfuss, A., Hoffmann, T., H.M., Barkhof, F. - on behalf of the ACCESS-AD Consortium

FACTS & FIGURES

Start date:	01-01-2026
End date:	31-12-2030
IHI funding:	20.190.282, 35 €
Industry contribution:	14.146.365 €
Contributing partners:	4.364.640 €
Total Cost:	38.701.287, 35 €
Project website:	www.access-ad.org
Social media:	www.linkedin.com/company/access-ad/

RESULTS

Expected outputs include an interoperable registry infrastructure and standardized core data model; validated, low-burden imaging, biofluid and digital monitoring solutions; AI/ML models and an integrated dashboard for both patients and caregivers; harmonized real-world evidence on DMT safety, usability and effectiveness; and guidance on primary-care involvement, lifestyle interventions and sustainable implementation. Together, these outputs will support more timely, personalized and accessible Alzheimer’s care across diverse healthcare systems in Europe.

PROJECT STRUCTURE

- COORDINATE:** Establish a robust project management framework, ensuring on-time delivery of the project milestones
- INTEGRATE:** Identify, integrate, and expand available data across Europe to counteract the fragmentation of knowledge collection
- DETECT:** Reduce patient access barriers tailored to local clinical workflows by further developing imaging, biofluid biomarkers, digital monitoring tools and clinical standardization
- STRATIFY:** Develop and deliver AI/ML based prediction models for tailored clinical decision-making workflows towards a precision medicine paradigm
- TREAT:** Collect real-world evidence on the safety, usability, and implementation of DMTs across diverse clinical settings, and explore emerging therapeutic approaches
- EVALUATE & SUSTAIN:** Integrating economic, regulatory and ethical aspects we will chart a sustainable pathway for uptake of new AD therapies, preparing Europe for a new era of AD therapy
- INVOLVE & ENGAGE:** Implement strategies for involvement, engagement, communication and dissemination, to strengthen the public awareness of this initiative, promote preventive healthcare measures and ensure that the needs and perspectives of people affected by dementia are considered

- 
 - Integrate multimodal diagnostics (neuroimaging, blood-based biomarkers, digital health tools), new treatments and real-world evidence
 - Deploy AI-driven decision support
 - Empower primary care and community settings
 - Build a sustainable European data and governance framework

CHALLENGE

Emerging disease-modifying therapies require biomarker-confirmed diagnosis, risk stratification and longitudinal safety monitoring. Across Europe, fragmented care pathways, heterogeneous data standards, limited access to imaging and fluid biomarkers, and healthcare-capacity constraints restrict equitable implementation. Insufficient validation of scalable diagnostic, digital and AI-enabled tools, and treatment personalization further limit the translation of scientific advances into routine clinical practice.

APPROACH & METHODOLOGY

ACCESS-AD applies a multimodal, patient-journey-based framework. Clinical and real-world data will be harmonized through a shared data model and infrastructure. Accelerated MRI, quantitative amyloid-PET, biofluid biomarkers, lifestyle interventions, and digital monitoring tools will be developed, validated, and implemented in clinical routine. AI/ML models will support prognosis, treatment-response prediction, and safety monitoring, complemented by patient and caregiver involvement as well as health-economic, regulatory, ethical and implementation analyses.

VALUE OF IHI COLLABORATION

The IHI public-private partnership integrates complementary expertise and assets from academia, healthcare, industry, patient organizations, and policy stakeholders. It provides access to multinational clinical settings, real-world datasets, imaging and biomarker technologies, AI and digital-health expertise, therapeutic-development knowledge and lived experience. This structure enables co-development and cross-setting validation while addressing regulatory, economic, and implementation requirements from the outset. In addition, the IHI provides a collaborative platform in which various projects can overlap and complement each other, therefore avoiding duplication of efforts.

CAREER IMPACT

Managing ACCESS-AD is advancing my career into a specialist in complex and diverse international research programs. The IHI public-private partnership allows me to develop expertise in consortium governance, cross-sector collaboration, stakeholder engagement, risk and grant management, and translating scientific priorities into coordinated delivery. These skills prepare me to lead future large-scale, multidisciplinary health research initiatives.

